0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Ketorolac Injection Market Research Report 2026
Published Date: 2026-01-28
|
Report Code: QYRE-Auto-24Z7589
Home | Market Reports | Health| Health Conditions| Pain Management
Global Ketorolac Injection Market Research Report 2022
BUY CHAPTERS

Global Ketorolac Injection Market Research Report 2026

Code: QYRE-Auto-24Z7589
Report
2026-01-28
Pages:130
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Ketorolac Injection Market Size

The global Ketorolac Injection market was valued at US$ 136 million in 2025 and is anticipated to reach US$ 197 million by 2032, at a CAGR of 2.7% from 2026 to 2032.

Ketorolac Injection Market

Ketorolac Injection Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Ketorolac Injection competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Ketorolac tromethamine injection is a prescription injectable nonsteroidal anti-inflammatory drug (NSAID) for short-term analgesia. Its active ingredient is a salt formed from ketorolac and tromethamine. It exerts its analgesic effect (and also has some anti-inflammatory and antipyretic properties) primarily by inhibiting cyclooxygenase (COX) to reduce prostaglandin production. This drug is typically used for short-term treatment of moderate to severe acute pain (commonly in perioperative or emergency pain management). It is characterized by its strong analgesic effect and reduced need for opioids. However, like other NSAIDs, it carries important safety risks such as gastrointestinal bleeding/ulceration, renal impairment, and bleeding. Therefore, strict control of the course of treatment and dosage is emphasized in clinical practice, and it must be used according to contraindications (such as active gastrointestinal bleeding, severe renal insufficiency, and high perioperative bleeding risk).
The demand for ketorolac tromethamine injection is essentially driven by the scenario of "short-term, intensive analgesia in hospitals." At the label level, it is positioned as a short-term (maximum of 5 days for adults) tool for managing moderate to severe acute pain, achieving "opioid-level analgesia requirements," which aligns particularly well with the clinical pathways for perioperative and emergency acute pain. Simultaneously, the massive number of surgeries performed globally each year and the continuous standardization of perioperative management have made "opioid-free/multimodal analgesia to reduce opioid use" a long-term trend, providing structural support for NSAID-based injectable analgesia. However, the market expansion of this product is naturally limited by its risk profile: the label explicitly emphasizes several important contraindications and warnings, including renal risk, bleeding risk, and contraindication in CABG surgery. Hospital medication management will more strongly constrain its use within the boundaries of "short treatment course, controllable population, and monitorable risk."
From a competitive landscape perspective, ketorolac injection represents a typical combination of a "mature, generic product + high barriers to entry in sterile injectable manufacturing": brand differentiation is limited, with competition primarily focused on sterile production and quality system capabilities, stable supply capabilities, packaging formats, and hospital compliance support (such as single-dose vials, barcodes and hospital dispensing friendliness, and channel coverage). In markets like the US, publicly available data shows that this product is supplied by multiple companies under different NDC/packaging company identities, including large generic injectable platforms (such as Pfizer and Fresenius Kabi) as well as multiple generic drug companies and packaging/distribution entities (such as Sun and Sagent), reflecting a multi-layered supply chain and price competition. For buyers (hospitals/group purchasing), evaluation dimensions often shift from "efficacy differences" to "supply disruption risk, compliance documentation, batch-to-batch consistency, and recall and change control history," which explains why manufacturing and quality management are given greater emphasis in procurement and market access for this type of product.
North America is the largest market, with a share about 40%, followed by Asia-Pacific and Europe with the share about 27% and 20%. In terms of product, 30mg/ml ketorolac injection is the largest segment, with a share over 64%. And in terms of application, the largest application is hospital, followed by clinics.
Future growth is more likely to stem from changes in "clinical pathways and delivery methods" rather than new selling points at the pharmacological level. On the one hand, the strengthening of multimodal analgesia in guidelines and academic consensus will drive hospitals to continuously optimize perioperative analgesia combinations and increase the weighting of non-opioid analgesia. Evidence is also accumulating regarding the effectiveness of NSAIDs in reducing postoperative pain and opioid usage when combined with regional anesthesia and glucocorticoids. On the other hand, safety and compliance requirements will continue to shape the market: the 5-day treatment limit and warnings about bleeding/kidney risk make it more suitable as a short-term tool rather than a long-term medication. Hospitals may place greater emphasis on tiered medication, perioperative bleeding risk management, and kidney function monitoring, thereby prompting companies to invest more in compliance with instructions, risk communication, and real-world medication management support. Meanwhile, given the frequent disruptions to the sterile injectable supply chain, suppliers that can provide more "ready-to-use/less error-prone" packaging specifications and have stable production capacity and consistent quality have a greater chance of gaining an advantage in centralized procurement/hospital access.
This report delivers a comprehensive overview of the global Ketorolac Injection market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Ketorolac Injection. The Ketorolac Injection market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Ketorolac Injection market comprehensively. Regional market sizes by Concentration, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Ketorolac Injection manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Concentration, by Application, and by region.
Market Segmentation

Scope of Ketorolac Injection Market Report

Report Metric Details
Report Name Ketorolac Injection Market
Accounted market size in 2025 US$ 136 million
Forecasted market size in 2032 US$ 197 million
CAGR 2.7%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Concentration
  • 15mg/ml
  • 30mg/ml
by Application
  • Hospital
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Fresenius Kabi, Sun Pharmaceutical, Sagent Pharmaceuticals, Baxter, Glenmark Pharmaceutical, Sola Pharmaceutical, TC Pharmaceuticals (Jiangsu) Co., Ltd, Lunan Pharm, Yunnan Longhai Natured Plant Pharmaceutical, Hairon Pharma, Sichuan Medcalo, Chengdu Brilliant Pharmaceuticals, Yung Shin Pharm, Tianjin Chase Sun Pharmaceutical, ZISKA Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Concentration, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Ketorolac Injection manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Ketorolac Injection sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Concentration, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Ketorolac Injection Market growing?

Ans: The Ketorolac Injection Market witnessing a CAGR of 2.7% during the forecast period 2026-2032.

What is the Ketorolac Injection Market size in 2032?

Ans: The Ketorolac Injection Market size in 2032 will be US$ 197 million.

What is the Ketorolac Injection Market share by region?

Ans: North America is the largest market, with a share about 40%, followed by Asia-Pacific and Europe with the share about 27% and 20%.

Who are the main players in the Ketorolac Injection Market report?

Ans: The main players in the Ketorolac Injection Market are Pfizer, Fresenius Kabi, Sun Pharmaceutical, Sagent Pharmaceuticals, Baxter, Glenmark Pharmaceutical, Sola Pharmaceutical, TC Pharmaceuticals (Jiangsu) Co., Ltd, Lunan Pharm, Yunnan Longhai Natured Plant Pharmaceutical, Hairon Pharma, Sichuan Medcalo, Chengdu Brilliant Pharmaceuticals, Yung Shin Pharm, Tianjin Chase Sun Pharmaceutical, ZISKA Pharmaceuticals

What are the Application segmentation covered in the Ketorolac Injection Market report?

Ans: The Applications covered in the Ketorolac Injection Market report are Hospital, Clinics, Others

1 Ketorolac Injection Market Overview
1.1 Product Definition
1.2 Ketorolac Injection by Concentration
1.2.1 Global Ketorolac Injection Market Value by Concentration: 2025 vs 2032
1.2.2 15mg/ml
1.2.3 30mg/ml
1.3 Ketorolac Injection by Application
1.3.1 Global Ketorolac Injection Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Global Ketorolac Injection Market Size Estimates and Forecasts
1.4.1 Global Ketorolac Injection Revenue 2021–2032
1.4.2 Global Ketorolac Injection Sales 2021–2032
1.4.3 Global Ketorolac Injection Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Ketorolac Injection Market Competition by Manufacturers
2.1 Global Ketorolac Injection Sales Market Share by Manufacturers (2021–2026)
2.2 Global Ketorolac Injection Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Ketorolac Injection Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Ketorolac Injection, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Ketorolac Injection, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Ketorolac Injection, Product Types and Applications
2.7 Global Key Manufacturers of Ketorolac Injection, Date of Entry into the Industry
2.8 Global Ketorolac Injection Market Competitive Situation and Trends
2.8.1 Global Ketorolac Injection Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Ketorolac Injection Players Market Share by Revenue
2.8.3 Global Ketorolac Injection Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Ketorolac Injection Market Scenario by Region
3.1 Global Ketorolac Injection Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Ketorolac Injection Sales by Region: 2021–2032
3.2.1 Global Ketorolac Injection Sales by Region: 2021–2026
3.2.2 Global Ketorolac Injection Sales by Region: 2027–2032
3.3 Global Ketorolac Injection Revenue by Region: 2021–2032
3.3.1 Global Ketorolac Injection Revenue by Region: 2021–2026
3.3.2 Global Ketorolac Injection Revenue by Region: 2027–2032
3.4 North America Ketorolac Injection Market Facts & Figures by Country
3.4.1 North America Ketorolac Injection Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Ketorolac Injection Sales by Country (2021–2032)
3.4.3 North America Ketorolac Injection Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Ketorolac Injection Market Facts & Figures by Country
3.5.1 Europe Ketorolac Injection Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Ketorolac Injection Sales by Country (2021–2032)
3.5.3 Europe Ketorolac Injection Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ketorolac Injection Market Facts & Figures by Region
3.6.1 Asia Pacific Ketorolac Injection Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Ketorolac Injection Sales by Region (2021–2032)
3.6.3 Asia Pacific Ketorolac Injection Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Ketorolac Injection Market Facts & Figures by Country
3.7.1 Latin America Ketorolac Injection Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Ketorolac Injection Sales by Country (2021–2032)
3.7.3 Latin America Ketorolac Injection Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ketorolac Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Ketorolac Injection Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Ketorolac Injection Sales by Country (2021–2032)
3.8.3 Middle East and Africa Ketorolac Injection Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Concentration
4.1 Global Ketorolac Injection Sales by Concentration (2021–2032)
4.1.1 Global Ketorolac Injection Sales by Concentration (2021–2026)
4.1.2 Global Ketorolac Injection Sales by Concentration (2027–2032)
4.1.3 Global Ketorolac Injection Sales Market Share by Concentration (2021–2032)
4.2 Global Ketorolac Injection Revenue by Concentration (2021–2032)
4.2.1 Global Ketorolac Injection Revenue by Concentration (2021–2026)
4.2.2 Global Ketorolac Injection Revenue by Concentration (2027–2032)
4.2.3 Global Ketorolac Injection Revenue Market Share by Concentration (2021–2032)
4.3 Global Ketorolac Injection Price by Concentration (2021–2032)
5 Segment by Application
5.1 Global Ketorolac Injection Sales by Application (2021–2032)
5.1.1 Global Ketorolac Injection Sales by Application (2021–2026)
5.1.2 Global Ketorolac Injection Sales by Application (2027–2032)
5.1.3 Global Ketorolac Injection Sales Market Share by Application (2021–2032)
5.2 Global Ketorolac Injection Revenue by Application (2021–2032)
5.2.1 Global Ketorolac Injection Revenue by Application (2021–2026)
5.2.2 Global Ketorolac Injection Revenue by Application (2027–2032)
5.2.3 Global Ketorolac Injection Revenue Market Share by Application (2021–2032)
5.3 Global Ketorolac Injection Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Pfizer Ketorolac Injection Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Fresenius Kabi
6.2.1 Fresenius Kabi Company Information
6.2.2 Fresenius Kabi Description and Business Overview
6.2.3 Fresenius Kabi Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Fresenius Kabi Ketorolac Injection Product Portfolio
6.2.5 Fresenius Kabi Recent Developments/Updates
6.3 Sun Pharmaceutical
6.3.1 Sun Pharmaceutical Company Information
6.3.2 Sun Pharmaceutical Description and Business Overview
6.3.3 Sun Pharmaceutical Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Sun Pharmaceutical Ketorolac Injection Product Portfolio
6.3.5 Sun Pharmaceutical Recent Developments/Updates
6.4 Sagent Pharmaceuticals
6.4.1 Sagent Pharmaceuticals Company Information
6.4.2 Sagent Pharmaceuticals Description and Business Overview
6.4.3 Sagent Pharmaceuticals Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Sagent Pharmaceuticals Ketorolac Injection Product Portfolio
6.4.5 Sagent Pharmaceuticals Recent Developments/Updates
6.5 Baxter
6.5.1 Baxter Company Information
6.5.2 Baxter Description and Business Overview
6.5.3 Baxter Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Baxter Ketorolac Injection Product Portfolio
6.5.5 Baxter Recent Developments/Updates
6.6 Glenmark Pharmaceutical
6.6.1 Glenmark Pharmaceutical Company Information
6.6.2 Glenmark Pharmaceutical Description and Business Overview
6.6.3 Glenmark Pharmaceutical Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Glenmark Pharmaceutical Ketorolac Injection Product Portfolio
6.6.5 Glenmark Pharmaceutical Recent Developments/Updates
6.7 Sola Pharmaceutical
6.7.1 Sola Pharmaceutical Company Information
6.7.2 Sola Pharmaceutical Description and Business Overview
6.7.3 Sola Pharmaceutical Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Sola Pharmaceutical Ketorolac Injection Product Portfolio
6.7.5 Sola Pharmaceutical Recent Developments/Updates
6.8 TC Pharmaceuticals (Jiangsu) Co., Ltd
6.8.1 TC Pharmaceuticals (Jiangsu) Co., Ltd Company Information
6.8.2 TC Pharmaceuticals (Jiangsu) Co., Ltd Description and Business Overview
6.8.3 TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Product Portfolio
6.8.5 TC Pharmaceuticals (Jiangsu) Co., Ltd Recent Developments/Updates
6.9 Lunan Pharm
6.9.1 Lunan Pharm Company Information
6.9.2 Lunan Pharm Description and Business Overview
6.9.3 Lunan Pharm Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Lunan Pharm Ketorolac Injection Product Portfolio
6.9.5 Lunan Pharm Recent Developments/Updates
6.10 Yunnan Longhai Natured Plant Pharmaceutical
6.10.1 Yunnan Longhai Natured Plant Pharmaceutical Company Information
6.10.2 Yunnan Longhai Natured Plant Pharmaceutical Description and Business Overview
6.10.3 Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Product Portfolio
6.10.5 Yunnan Longhai Natured Plant Pharmaceutical Recent Developments/Updates
6.11 Hairon Pharma
6.11.1 Hairon Pharma Company Information
6.11.2 Hairon Pharma Description and Business Overview
6.11.3 Hairon Pharma Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Hairon Pharma Ketorolac Injection Product Portfolio
6.11.5 Hairon Pharma Recent Developments/Updates
6.12 Sichuan Medcalo
6.12.1 Sichuan Medcalo Company Information
6.12.2 Sichuan Medcalo Description and Business Overview
6.12.3 Sichuan Medcalo Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Sichuan Medcalo Ketorolac Injection Product Portfolio
6.12.5 Sichuan Medcalo Recent Developments/Updates
6.13 Chengdu Brilliant Pharmaceuticals
6.13.1 Chengdu Brilliant Pharmaceuticals Company Information
6.13.2 Chengdu Brilliant Pharmaceuticals Description and Business Overview
6.13.3 Chengdu Brilliant Pharmaceuticals Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Chengdu Brilliant Pharmaceuticals Ketorolac Injection Product Portfolio
6.13.5 Chengdu Brilliant Pharmaceuticals Recent Developments/Updates
6.14 Yung Shin Pharm
6.14.1 Yung Shin Pharm Company Information
6.14.2 Yung Shin Pharm Description and Business Overview
6.14.3 Yung Shin Pharm Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Yung Shin Pharm Ketorolac Injection Product Portfolio
6.14.5 Yung Shin Pharm Recent Developments/Updates
6.15 Tianjin Chase Sun Pharmaceutical
6.15.1 Tianjin Chase Sun Pharmaceutical Company Information
6.15.2 Tianjin Chase Sun Pharmaceutical Description and Business Overview
6.15.3 Tianjin Chase Sun Pharmaceutical Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Tianjin Chase Sun Pharmaceutical Ketorolac Injection Product Portfolio
6.15.5 Tianjin Chase Sun Pharmaceutical Recent Developments/Updates
6.16 ZISKA Pharmaceuticals
6.16.1 ZISKA Pharmaceuticals Company Information
6.16.2 ZISKA Pharmaceuticals Description and Business Overview
6.16.3 ZISKA Pharmaceuticals Ketorolac Injection Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 ZISKA Pharmaceuticals Ketorolac Injection Product Portfolio
6.16.5 ZISKA Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ketorolac Injection Industry Chain Analysis
7.2 Ketorolac Injection Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ketorolac Injection Production Mode & Process Analysis
7.4 Ketorolac Injection Sales and Marketing
7.4.1 Ketorolac Injection Sales Channels
7.4.2 Ketorolac Injection Distributors
7.5 Ketorolac Injection Customer Analysis
8 Ketorolac Injection Market Dynamics
8.1 Ketorolac Injection Industry Trends
8.2 Ketorolac Injection Market Drivers
8.3 Ketorolac Injection Market Challenges
8.4 Ketorolac Injection Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Ketorolac Injection Market Value by Concentration (US$ Million), 2025 vs 2032
 Table 2. Global Ketorolac Injection Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Ketorolac Injection Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Ketorolac Injection Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Ketorolac Injection Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Ketorolac Injection Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Ketorolac Injection Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Ketorolac Injection Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Ketorolac Injection, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Ketorolac Injection, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Ketorolac Injection, Product Types and Applications
 Table 12. Global Key Manufacturers of Ketorolac Injection, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Ketorolac Injection Companies by Tier (Tier 1, Tier 2, Tier 3), based on Ketorolac Injection Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Ketorolac Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Ketorolac Injection Sales by Region (K Units), 2021–2026
 Table 18. Global Ketorolac Injection Sales Market Share by Region (2021–2026)
 Table 19. Global Ketorolac Injection Sales by Region (K Units), 2027–2032
 Table 20. Global Ketorolac Injection Sales Market Share by Region (2027–2032)
 Table 21. Global Ketorolac Injection Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Ketorolac Injection Revenue Market Share by Region (2021–2026)
 Table 23. Global Ketorolac Injection Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Ketorolac Injection Revenue Market Share by Region (2027–2032)
 Table 25. North America Ketorolac Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Ketorolac Injection Sales by Country (K Units), 2021–2026
 Table 27. North America Ketorolac Injection Sales by Country (K Units), 2027–2032
 Table 28. North America Ketorolac Injection Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Ketorolac Injection Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Ketorolac Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Ketorolac Injection Sales by Country (K Units), 2021–2026
 Table 32. Europe Ketorolac Injection Sales by Country (K Units), 2027–2032
 Table 33. Europe Ketorolac Injection Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Ketorolac Injection Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Ketorolac Injection Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Ketorolac Injection Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Ketorolac Injection Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Ketorolac Injection Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Ketorolac Injection Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Ketorolac Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Ketorolac Injection Sales by Country (K Units), 2021–2026
 Table 42. Latin America Ketorolac Injection Sales by Country (K Units), 2027–2032
 Table 43. Latin America Ketorolac Injection Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Ketorolac Injection Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Ketorolac Injection Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Ketorolac Injection Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Ketorolac Injection Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Ketorolac Injection Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Ketorolac Injection Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Ketorolac Injection Sales (K Units) by Concentration (2021–2026)
 Table 51. Global Ketorolac Injection Sales (K Units) by Concentration (2027–2032)
 Table 52. Global Ketorolac Injection Sales Market Share by Concentration (2021–2026)
 Table 53. Global Ketorolac Injection Sales Market Share by Concentration (2027–2032)
 Table 54. Global Ketorolac Injection Revenue (US$ Million) by Concentration (2021–2026)
 Table 55. Global Ketorolac Injection Revenue (US$ Million) by Concentration (2027–2032)
 Table 56. Global Ketorolac Injection Revenue Market Share by Concentration (2021–2026)
 Table 57. Global Ketorolac Injection Revenue Market Share by Concentration (2027–2032)
 Table 58. Global Ketorolac Injection Price (US$/Unit) by Concentration (2021–2026)
 Table 59. Global Ketorolac Injection Price (US$/Unit) by Concentration (2027–2032)
 Table 60. Global Ketorolac Injection Sales (K Units) by Application (2021–2026)
 Table 61. Global Ketorolac Injection Sales (K Units) by Application (2027–2032)
 Table 62. Global Ketorolac Injection Sales Market Share by Application (2021–2026)
 Table 63. Global Ketorolac Injection Sales Market Share by Application (2027–2032)
 Table 64. Global Ketorolac Injection Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Ketorolac Injection Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Ketorolac Injection Revenue Market Share by Application (2021–2026)
 Table 67. Global Ketorolac Injection Revenue Market Share by Application (2027–2032)
 Table 68. Global Ketorolac Injection Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Ketorolac Injection Price (US$/Unit) by Application (2027–2032)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Pfizer Ketorolac Injection Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Fresenius Kabi Company Information
 Table 76. Fresenius Kabi Description and Business Overview
 Table 77. Fresenius Kabi Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Fresenius Kabi Ketorolac Injection Product
 Table 79. Fresenius Kabi Recent Developments/Updates
 Table 80. Sun Pharmaceutical Company Information
 Table 81. Sun Pharmaceutical Description and Business Overview
 Table 82. Sun Pharmaceutical Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Sun Pharmaceutical Ketorolac Injection Product
 Table 84. Sun Pharmaceutical Recent Developments/Updates
 Table 85. Sagent Pharmaceuticals Company Information
 Table 86. Sagent Pharmaceuticals Description and Business Overview
 Table 87. Sagent Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Sagent Pharmaceuticals Ketorolac Injection Product
 Table 89. Sagent Pharmaceuticals Recent Developments/Updates
 Table 90. Baxter Company Information
 Table 91. Baxter Description and Business Overview
 Table 92. Baxter Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Baxter Ketorolac Injection Product
 Table 94. Baxter Recent Developments/Updates
 Table 95. Glenmark Pharmaceutical Company Information
 Table 96. Glenmark Pharmaceutical Description and Business Overview
 Table 97. Glenmark Pharmaceutical Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Glenmark Pharmaceutical Ketorolac Injection Product
 Table 99. Glenmark Pharmaceutical Recent Developments/Updates
 Table 100. Sola Pharmaceutical Company Information
 Table 101. Sola Pharmaceutical Description and Business Overview
 Table 102. Sola Pharmaceutical Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Sola Pharmaceutical Ketorolac Injection Product
 Table 104. Sola Pharmaceutical Recent Developments/Updates
 Table 105. TC Pharmaceuticals (Jiangsu) Co., Ltd Company Information
 Table 106. TC Pharmaceuticals (Jiangsu) Co., Ltd Description and Business Overview
 Table 107. TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. TC Pharmaceuticals (Jiangsu) Co., Ltd Ketorolac Injection Product
 Table 109. TC Pharmaceuticals (Jiangsu) Co., Ltd Recent Developments/Updates
 Table 110. Lunan Pharm Company Information
 Table 111. Lunan Pharm Description and Business Overview
 Table 112. Lunan Pharm Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Lunan Pharm Ketorolac Injection Product
 Table 114. Lunan Pharm Recent Developments/Updates
 Table 115. Yunnan Longhai Natured Plant Pharmaceutical Company Information
 Table 116. Yunnan Longhai Natured Plant Pharmaceutical Description and Business Overview
 Table 117. Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Yunnan Longhai Natured Plant Pharmaceutical Ketorolac Injection Product
 Table 119. Yunnan Longhai Natured Plant Pharmaceutical Recent Developments/Updates
 Table 120. Hairon Pharma Company Information
 Table 121. Hairon Pharma Description and Business Overview
 Table 122. Hairon Pharma Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. Hairon Pharma Ketorolac Injection Product
 Table 124. Hairon Pharma Recent Developments/Updates
 Table 125. Sichuan Medcalo Company Information
 Table 126. Sichuan Medcalo Description and Business Overview
 Table 127. Sichuan Medcalo Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 128. Sichuan Medcalo Ketorolac Injection Product
 Table 129. Sichuan Medcalo Recent Developments/Updates
 Table 130. Chengdu Brilliant Pharmaceuticals Company Information
 Table 131. Chengdu Brilliant Pharmaceuticals Description and Business Overview
 Table 132. Chengdu Brilliant Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 133. Chengdu Brilliant Pharmaceuticals Ketorolac Injection Product
 Table 134. Chengdu Brilliant Pharmaceuticals Recent Developments/Updates
 Table 135. Yung Shin Pharm Company Information
 Table 136. Yung Shin Pharm Description and Business Overview
 Table 137. Yung Shin Pharm Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 138. Yung Shin Pharm Ketorolac Injection Product
 Table 139. Yung Shin Pharm Recent Developments/Updates
 Table 140. Tianjin Chase Sun Pharmaceutical Company Information
 Table 141. Tianjin Chase Sun Pharmaceutical Description and Business Overview
 Table 142. Tianjin Chase Sun Pharmaceutical Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 143. Tianjin Chase Sun Pharmaceutical Ketorolac Injection Product
 Table 144. Tianjin Chase Sun Pharmaceutical Recent Developments/Updates
 Table 145. ZISKA Pharmaceuticals Company Information
 Table 146. ZISKA Pharmaceuticals Description and Business Overview
 Table 147. ZISKA Pharmaceuticals Ketorolac Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 148. ZISKA Pharmaceuticals Ketorolac Injection Product
 Table 149. ZISKA Pharmaceuticals Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Ketorolac Injection Distributors List
 Table 153. Ketorolac Injection Customers List
 Table 154. Ketorolac Injection Market Trends
 Table 155. Ketorolac Injection Market Drivers
 Table 156. Ketorolac Injection Market Challenges
 Table 157. Ketorolac Injection Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Ketorolac Injection
 Figure 2. Global Ketorolac Injection Market Value by Concentration (US$ Million), 2021–2032
 Figure 3. Global Ketorolac Injection Market Share by Concentration: 2025 & 2032
 Figure 4. 15mg/ml Product Picture
 Figure 5. 30mg/ml Product Picture
 Figure 6. Global Ketorolac Injection Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Ketorolac Injection Market Share by Application: 2025 & 2032
 Figure 8. Hospital
 Figure 9. Clinics
 Figure 10. Others
 Figure 11. Global Ketorolac Injection Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global Ketorolac Injection Market Size (US$ Million), 2021–2032
 Figure 13. Global Ketorolac Injection Sales (K Units), 2021–2032
 Figure 14. Global Ketorolac Injection Average Price (US$/Unit), 2021–2032
 Figure 15. Ketorolac Injection Report Years Considered
 Figure 16. Ketorolac Injection Sales Share by Manufacturers in 2025
 Figure 17. Global Ketorolac Injection Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global Ketorolac Injection Players: Market Share by Revenue in Ketorolac Injection in 2025
 Figure 19. Ketorolac Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global Ketorolac Injection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America Ketorolac Injection Sales Market Share by Country (2021–2032)
 Figure 22. North America Ketorolac Injection Revenue Market Share by Country (2021–2032)
 Figure 23. United States Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe Ketorolac Injection Sales Market Share by Country (2021–2032)
 Figure 26. Europe Ketorolac Injection Revenue Market Share by Country (2021–2032)
 Figure 27. Germany Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific Ketorolac Injection Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific Ketorolac Injection Revenue Market Share by Region (2021–2032)
 Figure 34. China Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Indonesia Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Thailand Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Malaysia Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Latin America Ketorolac Injection Sales Market Share by Country (2021–2032)
 Figure 44. Latin America Ketorolac Injection Revenue Market Share by Country (2021–2032)
 Figure 45. Mexico Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Brazil Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Argentina Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Middle East and Africa Ketorolac Injection Sales Market Share by Country (2021–2032)
 Figure 49. Middle East and Africa Ketorolac Injection Revenue Market Share by Country (2021–2032)
 Figure 50. Turkey Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Saudi Arabia Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. UAE Ketorolac Injection Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Global Sales Market Share of Ketorolac Injection by Concentration (2021–2032)
 Figure 54. Global Revenue Market Share of Ketorolac Injection by Concentration (2021–2032)
 Figure 55. Global Ketorolac Injection Price (US$/Unit) by Concentration (2021–2032)
 Figure 56. Global Sales Market Share of Ketorolac Injection by Application (2021–2032)
 Figure 57. Global Revenue Market Share of Ketorolac Injection by Application (2021–2032)
 Figure 58. Global Ketorolac Injection Price (US$/Unit) by Application (2021–2032)
 Figure 59. Ketorolac Injection Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD